Regenxbio IncNASDAQ:RGNX
- LAST PRICE16.3240
- TODAY'S CHANGE (%)0.5240 (3.3165%)
- Bid / Lots16.3200/ 2
- Ask / Lots16.3600/ 2
- Open / Previous Close16.2800 / 15.8000
- Day Range
- 52 Week Range
- Volume139,655
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 12744 | 16.34 |
| 09:34 ET | 6567 | 16.57 |
| 09:36 ET | 1137 | 16.575 |
| 09:38 ET | 1856 | 16.7129 |
| 09:39 ET | 3557 | 16.65 |
| 09:41 ET | 1000 | 16.58 |
| 09:43 ET | 795 | 16.52 |
| 09:45 ET | 1017 | 16.53 |
| 09:48 ET | 700 | 16.48 |
| 09:50 ET | 1743 | 16.49 |
| 09:52 ET | 824 | 16.465 |
| 09:54 ET | 3827 | 16.4 |
| 09:56 ET | 1517 | 16.355 |
| 09:57 ET | 900 | 16.3 |
| 09:59 ET | 300 | 16.26 |
| 10:01 ET | 100 | 16.245 |
| 10:03 ET | 500 | 16.235 |
| 10:06 ET | 100 | 16.2 |
| 10:08 ET | 200 | 16.1 |
| 10:10 ET | 993 | 16.165 |
| 10:12 ET | 625 | 16.24 |
| 10:14 ET | 100 | 16.235 |
| 10:15 ET | 573 | 16.2 |
| 10:17 ET | 330 | 16.25 |
| 10:21 ET | 100 | 16.25 |
| 10:24 ET | 200 | 16.265 |
| 10:30 ET | 200 | 16.19 |
| 10:32 ET | 617 | 16.203 |
| 10:37 ET | 100 | 16.18 |
| 10:39 ET | 5337 | 16.08 |
| 10:42 ET | 1008 | 16.1 |
| 10:44 ET | 200 | 16.1 |
| 10:46 ET | 5854 | 16.16 |
| 10:48 ET | 700 | 16.155 |
| 10:50 ET | 500 | 16.18 |
| 10:51 ET | 521 | 16.23 |
| 10:53 ET | 537 | 16.2 |
| 10:57 ET | 200 | 16.23 |
| 11:00 ET | 326 | 16.25 |
| 11:02 ET | 300 | 16.255 |
| 11:04 ET | 800 | 16.27 |
| 11:06 ET | 400 | 16.23 |
| 11:08 ET | 100 | 16.21 |
| 11:11 ET | 100 | 16.21 |
| 11:18 ET | 100 | 16.21 |
| 11:20 ET | 444 | 16.225 |
| 11:22 ET | 1400 | 16.25 |
| 11:24 ET | 8603 | 16.41 |
| 11:26 ET | 600 | 16.425 |
| 11:27 ET | 100 | 16.43 |
| 11:31 ET | 100 | 16.39 |
| 11:33 ET | 100 | 16.385 |
| 11:36 ET | 400 | 16.42 |
| 11:38 ET | 907 | 16.435 |
| 11:40 ET | 300 | 16.415 |
| 11:42 ET | 100 | 16.4 |
| 11:44 ET | 421 | 16.39 |
| 11:45 ET | 800 | 16.41 |
| 11:47 ET | 2656 | 16.35 |
| 11:49 ET | 3308 | 16.31 |
| 11:51 ET | 3802 | 16.31 |
| 11:54 ET | 4733 | 16.48 |
| 11:56 ET | 4618 | 16.44 |
| 11:58 ET | 900 | 16.43 |
| 12:02 ET | 1100 | 16.42 |
| 12:03 ET | 500 | 16.39 |
| 12:05 ET | 100 | 16.38 |
| 12:07 ET | 200 | 16.375 |
| 12:12 ET | 200 | 16.405 |
| 12:14 ET | 720 | 16.385 |
| 12:18 ET | 100 | 16.36 |
| 12:20 ET | 200 | 16.36 |
| 12:21 ET | 500 | 16.32 |
| 12:23 ET | 1141 | 16.33 |
| 12:25 ET | 535 | 16.345 |
| 12:27 ET | 800 | 16.35 |
| 12:30 ET | 100 | 16.324 |
Today
DJ REGENXBIO Is Maintained at Buy by HC Wainwright & Co., from 1 hour ago by Dow Jones
1 hour ago by Dow Jones
May 10, 2024
REGENXBIO to Participate in Upcoming Investor Conferences, from 7:05AM ET on Friday May 10, 2024 by Dow Jones
7:05AM ET on Friday May 10, 2024 by Dow Jones
May 8, 2024
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow Jones*DJ REGENXBIO 1Q Loss/Shr $1.38 >RGNX, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
4:05PM ET on Wednesday May 08, 2024 by Dow Jones
May 1, 2024
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights, from 7:05AM ET on Wednesday May 01, 2024 by Dow Jones
7:05AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 774.9M | -2.8x | --- |
SAGE Therapeutics Inc | 721.6M | -1.4x | --- |
Nurix Therapeutics Inc | 886.6M | -6.2x | --- |
CureVac NV | 695.3M | -2.5x | --- |
WAVE Life Sciences Ltd | 714.3M | -11.6x | --- |
Zymeworks Inc | 636.3M | -5.1x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Allan Fox
- President, Chief Executive Officer, Director
- Kenneth Mills
- Chief Financial Officer, Executive Vice President
- Vittal Vasista
- Chief Operating Officer, Executive Vice President
- Curran Simpson
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $774.9M |
|---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.36 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 8.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
